ImmunoGen, Inc. (IMGN) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Waltham, MA, アメリカ. 現CEOは Mark Joseph Enyedy.
IMGN を有する IPO日 1989-11-17, 277 名の正社員, に上場 NASDAQ Global Select, 時価総額 $8.73B.
ImmunoGen, Inc. is a clinical-stage biotechnology company focused on developing antibody-drug conjugate (ADC) therapies for cancer treatment. The company's lead candidate, mirvetuximab soravtansine, targets folate-receptor alpha and is in Phase III trials for platinum-resistant ovarian cancer, while Pivekimab sunirine, a CD123-targeting ADC, is in Phase II development for acute myeloid leukemia and related blood cancers. ImmunoGen maintains a robust pipeline of preclinical programs and strategic collaborations with major pharmaceutical companies including Roche, Amgen, Bayer, Eli Lilly, Novartis, and others. Founded in 1980 and headquartered in Waltham, Massachusetts, the company leverages proprietary ADC technology to advance novel cancer therapies.
